Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 3/2021

01-03-2021 | COVID-19 Vaccination | Review

SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis

Authors: Tsvetelina Velikova, Tsvetoslav Georgiev

Published in: Rheumatology International | Issue 3/2021

Login to get access

Abstract

Coronavirus disease 2019 (COVID-19) pandemic has become challenging even for the most durable healthcare systems. It seems that vaccination, one of the most effective public-health interventions, presents a ray of hope to end the pandemic by achieving herd immunity. In this review, we aimed to cover aspects of the current knowledge of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines and vaccine candidates in the light of autoimmune inflammatory diseases (AIIDs) and to analyze their potential in terms of safety and effectiveness in patients with AIIDs. Therefore, a focused narrative review was carried out to predict the possible implications of different types of SARS-CoV-2 vaccines which confer distinct immune mechanisms to establish immune response and protection against COVID-19: whole virus (inactivated or weakened), viral vector (replicating and non-replicating), nucleic acid (RNA, DNA), and protein-based (protein subunit, virus-like particle). Still, there is uncertainty among patients with AIIDs and clinicians about the effectiveness and safety of the new vaccines. There are a variety of approaches towards building a protective immunity against SARS-CoV-2. Only high-quality clinical trials would clarify the underlying immunological mechanisms of the newly implemented vaccines/adjuvants in patients living with AIIDs.
Literature
1.
Lambert H, Gupte J, Fletcher H, Hammond L, Lowe N, Pelling M et al (2020) COVID-19 as a global challenge: towards an inclusive and sustainable future. Lancet Planet Health 4(8):e312-314PubMedCrossRef
2.
Haug N, Geyrhofer L, Londei A, Dervic E, Desvars-Larrive A, Loreto V, Pinior B, Thurner S, Klimek P (2020) Ranking the effectiveness of worldwide COVID-19 government interventions. Nat Hum Behav 4(12):1303–1312PubMedCrossRef
3.
4.
Georgiev T, Angelov AK (2020) Complexities of diagnosis and management of COVID-19 in autoimmune diseases: potential benefits and detriments of immunosuppression. World J Clin Cases 8(17):3669–3678PubMedPubMedCentralCrossRef
5.
Fontanet A, Cauchemez S (2020) COVID-19 herd immunity: where are we? Nat Rev Immunol 20(10):583–584PubMedCrossRef
6.
Saxena S, Skirrow H, Bedford H (2020) Routine vaccination during covid-19 pandemic response. BMJ 369:m2392PubMedCrossRef
7.
Burgess RA, Osborne RH, Yongabi KA, Greenhalgh T, Gurdasani D, Kang G et al (2020) The COVID-19 vaccines rush: participatory community engagement matters more than ever. Lancet S0140673620326428
8.
9.
Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31(11):1409–1417PubMedCrossRef
10.
11.
Galeotti C, Bayry J (2020) Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol 16(8):413–414PubMedCrossRef
12.
Misra DP, Agarwal V, Gasparyan AY, Zimba O (2020) Rheumatologists’ perspective on Coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol 39(7):2055–2062PubMedCrossRef
13.
14.
15.
Kipps S, Paul A, Vasireddy S (2020) Incidence of COVID-19 in patients with rheumatic disease: is prior health education more important than shielding advice during the pandemic? Clin Rheumatol 11:1–5
16.
Serling-Boyd N, D'Silva KM, Hsu TY, Wallwork R, Fu X, Gravallese EM et al (2020) Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic. Ann Rheum Dis
17.
Baker D, Roberts CAK, Pryce G, Kang AS, Marta M, Reyes S et al (2020) COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol 202(2):149–161PubMedCrossRef
18.
Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M et al (2020) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79(1):39–52PubMedCrossRef
19.
Ahmed S, Gasparyan AY, Zimba O (2021) Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic. Rheumatol Int 41:243–256PubMedCrossRef
20.
21.
Agmon-Levin N, Paz Z, Israeli E, Shoenfeld Y (2009) Vaccines and autoimmunity. Nat Rev Rheumatol 5:648–652PubMedCrossRef
22.
Schattner A (2005) Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 23:3876–3886PubMedCrossRef
23.
Salemi S, D’Amelio R (2010) Could autoimmunity be induced by vaccination? Int Rev Immunol 29:47–69CrossRef
24.
Vadalà M, Poddighe D, Laurino C, Palmieri B (2017) Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon? EPMA J 8(3):295–311PubMedPubMedCentralCrossRef
25.
De Martino M, Chiappini E, Galli L (2013) Vaccines and autoimmunity. Int J Immunopathol Pharmacol 26(2):283–290PubMedCrossRef
26.
Rodríguez Y, Rojas M, Pacheco Y, Acosta-Ampudia Y, Ramírez-Santana C, Monsalve DM et al (2018) Guillain–Barré syndrome, transverse myelitis and infectious diseases. Cell Mol Immunol 15(6):547–562PubMedPubMedCentralCrossRef
27.
Markovic-Plese S, Hemmer B, Zhao Y, Simon R, Pinilla C, Martin R (2005) High level of cross-reactivity in influenza virus hemagglutinin-specific CD4+ T cell response: implications for the initiation of autoimmune response in multiple sclerosis. J Neuroimmunol 169(1–2):31–38PubMedCrossRef
28.
Sioofy-Khojine AB, Lehtonen J, Nurminen N, Laitinen OH, Oikarinen S, Huhtala H et al (2018) Coxsackievirus B1 infections are associated with the initiation of insulin-driven autoimmunity that progresses to type 1 diabetes. Diabetologia 61(5):1193–1202PubMedCrossRef
29.
Takahashi Y, Murai C, Shibata S, Munakata Y, Ishii T, Ishii K et al (1998) Human parvovirus B19 as a causative agent for rheumatoid arthritis. Proc Natl Acad Sci USA 95(14):8227–8232PubMedCrossRef
30.
Institute of Medicine (2011) Adverse effects of vaccines: evidence and causality. The National Academies Press, Washington DC
31.
Kivity S, Agmon-Levin N, Blank M, Shoenfeld Y (2009) Infections and autoimmunity-friends or foes? Trends Immunol 30:409–414PubMedCrossRef
32.
33.
Chen RT, Pless R, De Stefano F (2001) Epidemiology of autoimmune reactions induced by vaccination. J Autoimmun 16(3):309–318PubMedCrossRef
34.
35.
Colmegna I, Useche ML, Rodriguez K, McCormack D, Alfonso G, Patel A et al (2019) Immunogenicity and safety of high-dose versus standard-dose inactivated influenza vaccine in rheumatoid arthritis patients: a randomised, double-blind, active-compatator trial. Lancet Rheum 2(1):E14–E23CrossRef
36.
Flanagan KL, Fink AL, Plebanski M, Klein SL (2017) Sex and gender differences in the outcomes of vaccination over the life course. Annu Rev Cell Dev Biol 33:577–599PubMedCrossRef
37.
Dhakal S, Klein SL (2019) Host factors impact vaccine efficacy: implications for seasonal and universal influenza vaccine programs. J Virol 93(21):e00797-e819PubMedPubMedCentralCrossRef
38.
Sheridan PA, Paich HA, Handy J, Karlsson EA, Hudgens MG, Sammon AB et al (2012) Obesity is associated with impaired immune response to influenza vaccination in humans. Int J Obes 36:1072–1077CrossRef
39.
Campos LM, Silva CA, Aikawa NE, Jesus AA, Moraes JC, Miraglia J et al (2013) High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken) 65(7):1121–1127CrossRef
40.
41.
Lurie N, Saville M, Hatchett R, Halton J (2020) Developing COVID-19 vaccines at pandemic speed. N Engl J Med 382(21):1969–1973PubMedCrossRef
42.
Le Thanh T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S (2020) The COVID-19 vaccine development landscape. Nat Rev Drug Discov 19(5):305–306CrossRef
43.
Chang CC, Chang YS, Chen WS, Chen YH, Chen JH (2016) Effects of annual influenza vaccination on morbidity and mortality in patients with systemic lupus erythematosus: a nationwide cohort study. Sci Rep 6:37817PubMedPubMedCentralCrossRef
44.
Kostianovsky A, Charles P, Alves JF, Goulet M, Pagnoux C, Le Guern V et al (2012) French Vasculitis Study Group. Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients. Clin Exp Rheumatol 30:S83–S89PubMed
45.
Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I et al (2008) Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 67(7):937–941PubMedCrossRef
46.
Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ et al (2015) Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 372(22):2087–2096PubMedCrossRef
47.
Custers J, Kim D, Leyssen M, Gurwith M, Tomaka F, Robertson J et al (2020) Vaccines based on replication incompetent Ad26 viral vectors: standardized template with key considerations for a risk/benefit assessment. Vaccine
48.
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK et al (2020) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397(10269):99–111PubMedPubMedCentralCrossRef
49.
De Haan P, Van Diemen FR, Toscano MG (2020) Viral gene delivery vectors: the next generation medicines for immune-related diseases. Hum Vaccin Immunother 15:1–8
50.
51.
52.
Sahin U, Kariko K, Tureci O (2014) mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discov 13:759–780PubMedCrossRef
53.
54.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S et al (2020) Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 383:2603–2615PubMedCrossRef
55.
Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D (2008) Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 16(11):1833–1840PubMedPubMedCentralCrossRef
56.
Kauffman KJ, Webber MJ, Anderson DG (2016) Materials for non-viral intracellular delivery of messenger RNA therapeutics. J Control Release 240:227–234PubMedCrossRef
57.
Guan S, Rosenecker J (2017) Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems. Gene Ther 24:133–143PubMedCrossRef
58.
Thess A, Grund S, Mui BL, Hope MJ, Baumhof P, Fotin-Mleczek M, Schlake T (2015) Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals. Mol Ther 23(9):1456–1464PubMedPubMedCentralCrossRef
59.
Kariko K, Muramatsu H, Ludwig J, Weissman D (2011) Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res 39:e142PubMedPubMedCentralCrossRef
60.
Isaacs A, Cox RA, Rotem Z (1963) Foreign nucleic acids as the stimulus to make interferon. Lancet 2:113–116PubMedCrossRef
61.
Edwards DK, Jasny E, Yoon H, Horscroft N, Schanen B, Geter T et al (2017) Adjuvant effects of a sequence-engineered mRNA vaccine: translational profiling demonstrates similar human and murine innate response. J Transl Med 15(1):1PubMedPubMedCentralCrossRef
62.
Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z (2020) Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol 20(10):615–632PubMedCrossRef
63.
Metadata
Title
SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis
Authors
Tsvetelina Velikova
Tsvetoslav Georgiev
Publication date
01-03-2021
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 3/2021
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-021-04792-9

Other articles of this Issue 3/2021

Rheumatology International 3/2021 Go to the issue

Case Based Review

Successful use of tofacitinib in the treatment of diffuse systemic sclerosis and axial spondyloarthritis: a case-based review

Correspondence

Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19

Expert Opinion

Enhancing rheumatology education during the COVID-19 pandemic

Observational Research

Macrophage activation syndrome in systemic lupus erythematosus and systemic-onset juvenile idiopathic arthritis: a retrospective study of similarities and dissimilarities

Observational Research

Psychosocial and clinical effects of the COVID-19 pandemic in patients with childhood rheumatic diseases and their parents

Imaging

Spleen elastography in patients with Systemic sclerosis

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits